Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan
Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization application to the European Medicines Agency for Selincro (nalmefene), the company's novel opioid receptor ligand in development for alcohol dependence and the dossier has been accepted for review by EMA.
Lundbeck licensed the rights to Selincro from Finland’s Biotie Therapeutics, under the terms of which Biotie received an execution fee of 12 million euros ($15.6 million). In total, Biotie is eligible for up to 84 million euros in upfront and milestone payments plus royalty on sales. Lundbeck will be responsible for manufacturing and registration of the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze